<DOC>
	<DOCNO>NCT01599078</DOCNO>
	<brief_summary>The purpose study assess safety efficacy administer intra-arterial paclitaxel femoropopliteal artery via TAPAS catheter follow percutaneous revascularization prevent restenosis .</brief_summary>
	<brief_title>Local Delivery Paclitaxel Via TAPAS Catheter Prevent Restenosis From Percutaneous Femoropopliteal Intervention</brief_title>
	<detailed_description>Peripheral artery disease ( PAD ) low extremity extremely prevalent disorder important cause morbidity affect 10 million people United States . This disorder typically cause atherosclerosis limit blood flow limb , particularly due stenosis occlusion superficial femoral artery ( SFA ) and/or popliteal artery . Although many patient asymptomatic treat lifestyle change , exercise therapy , pharmacological treatment , include statin anti-platelet therapy , 10-15 % patient progressive symptom severe case may lead amputation . Endovascular treatment percutaneous vascular intervention ( PVI ) , include percutaneous transluminal angioplasty ( PTA ) , stenting , atherectomy thrombolytic therapy , provide excellent acute success rate great 90-95 % However , intermediate long-term patency rate artery hamper neointimal hyperplasia result restenosis artery . This occur endovascular therapy degree coronary peripheral arena . With PVI superficial femoral popliteal artery restenosis rate approximately 30-40 % 12 month , depend complexity severity disease . In coronary field , stent coat anti-restenotic pharmacologic agent ( drug elute stents—DES ) paclitaxel sirolimus-like drug prevent neointimal growth . There publish report significant efficacy prevent restenosis SFA coating balloon paclitaxel ( drug elute balloons—DEB ) well nitinol stent . Despite fact product CE Mark approve available Europe , currently US FDA approve drug-eluting device use PVI . Thus , remain need alternative therapy prevent restenosis SFA follow endovascular intervention . Administration intra-arterial paclitaxel mixed iodinate contrast show inhibit restenosis porcine coronary model . Delivering paclitaxel intra-arterially coronary tree follow stent implantation show benefit reduce incidence restenosis . The novel Targeted Adjustable Pharmaceutical Application System ( TAPAS ) —TAPAS Catheter Therapeutic Infusion System ( ThermopeutiX , San Diego , CA , USA ) —is drug delivery catheter consist proximal distal occlusion balloon adjustable length allow drug dwell specific segment artery period time . The drug aspirate discarded avoid systemic exposure . The PacTAP study randomize , double blind , placebo-control study assess safety efficacy deliver intra-arterial paclitaxel via TAPAS catheter follow PVI prevent restenosis .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age ≥ 18 year old . Subject able provide inform consent agree follow requirement . Peripheral arterial disease Rutherford Class 25 . Successful percutaneous revascularization femoropopliteal artery ( &lt; 20 % residual stenosis visual estimate ) use standard technique per discretion local operator . The femoropopliteal Reference Vessel Diameter ( RVD ) must ≥4.0 mm ≤7.0 mm Patient pregnant breast feeding . ( Female subject childbearing potential must negative serum pregnancy test day procedure . ) Life expectancy &lt; 12 month . Contraindication aspirin , antiplatelet/anticoagulant therapy require procedure/follow . Known allergy contrast medium adequately premedicated prior study procedure . Known allergy paclitaxel . Uncontrolled hypercoagulability history HIT HITTS syndrome . Simultaneous enrollment another investigational device drug study . Previous intervention target limb drug elute stent drug elute balloon . Absence least 1 TIMI3 vessel run foot . Total bilirubin &gt; 2x upper limit normal ( ULN ) . ALT AST &gt; 3x ULN . Platelet count &lt; 100,000/mm3 . White blood cell count &lt; 1.5/mm3 . Any evidence perforation dye extravasation index procedure , even successfully treat covered stent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Restenosis</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Stent</keyword>
	<keyword>Atherectomy</keyword>
	<keyword>Femoral Artery</keyword>
	<keyword>Popliteal Artery</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>